Given the epidemiology of polysubstance
use, patients, health professionals and regulatory bodies
should be aware that such drugs present an increased risk of slowing
down alcohol metabolism, which may result in potentially toxic
plasma alcohol concentrations and the related alcohol–health consequences,
causing associate risk behavioral impairment along with
psychosocial, legal and forensic implications